Business | Tuesday December 17, 2013
The announcement appears to be a first for a major drug company - although others may be considering similar moves - and it comes at a particularly sensitive time for Glaxo. It is the subject of a bribery investigation in China, where authorities contend the company funneled illegal payments to doctors and government officials in an effort to lift ...
www.ndtv.com/business